相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study
Pierre Van Damme et al.
BMC INFECTIOUS DISEASES (2010)
Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic
Magali Lemaitre et al.
BMC INFECTIOUS DISEASES (2010)
Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents
Vincenzo Baldo et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
Immunogenicity and Safety of Intradermal Influenza Vaccination in Healthy Older Adults
Ru-Chien Chi et al.
CLINICAL INFECTIOUS DISEASES (2010)
Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years Randomized, controlled, phase III trial
Robert Arnou et al.
HUMAN VACCINES (2010)
Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials
Eric Plennevaux et al.
LANCET (2010)
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
Xiao-Feng Liang et al.
LANCET (2010)
Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial
Zoltan Vajo et al.
LANCET (2010)
Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus
Surender Khurana et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Vaccine adjuvants: A priority for vaccine research
Ali M. Harandi et al.
VACCINE (2010)
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates
Filippo Ansaldi et al.
VACCINE (2010)
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial
Francois Roman et al.
VACCINE (2010)
Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study
Isabel Leroux-Roels et al.
VACCINE (2010)
Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months
Alfonso Carmona et al.
VACCINE (2010)
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
Claire S. Waddington et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Randomized, Double-Blind Comparative Trial of Subunit and Virosomal Influenza Vaccines for Immunocompromised Patients
John Evison et al.
CLINICAL INFECTIOUS DISEASES (2009)
Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older
Ann R. Falsey et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine.
Tristan W. Clark et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
New horizons in adjuvants for vaccine development
Steven G. Reed et al.
TRENDS IN IMMUNOLOGY (2009)
Influenza control in the 21st century: Optimizing protection of older adults
Arnold S. Monto et al.
VACCINE (2009)
Eleven years of Inflexal® V-a virosomal adjuvanted influenza vaccine
Christian Herzog et al.
VACCINE (2009)
Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults
Daniel Wai-Sing Chu et al.
VACCINE (2009)
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults
Rebecca C. Brady et al.
VACCINE (2009)
Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection
Filippo Ansaldi et al.
VACCINE (2009)
Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study
Robert Arnou et al.
VACCINE (2009)
Mechanism of action of licensed vaccine adjuvants
Elaine Tritto et al.
VACCINE (2009)
Biology of immune responses to vaccines in elderly persons
Birgit Weinberger et al.
CLINICAL INFECTIOUS DISEASES (2008)
Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice
Jean-Francois Nicolas et al.
EXPERT REVIEW OF VACCINES (2008)
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses
Benoit Baras et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2008)
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: Results of a phase I-II randomized clinical trial
Wendy A. Keitel et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults
David I. Bernstein et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: A randomized controlled trial
David Holland et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Molecular and cellular signatures of human vaccine adjuvants
F. Mosca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?
Paul Henri Lambert et al.
VACCINE (2008)
Cross-protection by MF59™-adjuvanted influenza vaccine:: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses
Filippo Ansaldi et al.
VACCINE (2008)
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Rongcheng Li et al.
Immunity & Ageing (2008)
Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly
Iris de Bruijn et al.
VACCINE (2007)
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects
Robert B. Couch et al.
VACCINE (2007)
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
Derek T. O'Hagan
EXPERT REVIEW OF VACCINES (2007)
Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases
V. Baldo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2007)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
The virosomal influenza vaccine Invivac®:: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad®) in elderly subjects
I. A. de Bruijn et al.
VACCINE (2006)
Response to influenza vaccine in people with non-protective HI antibody titers
Vincenzo Baldo et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2006)
Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene
Giuseppe Del Giudice et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine
Noriko Kojimahara et al.
VACCINE (2006)
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons
Wendy A. Keitel et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
Jean-Louis Bresson et al.
LANCET (2006)
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
G Del Giudice et al.
VACCINE (2006)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
JJ Treanor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Antibody response to influenza vaccination in the elderly: A quantitative review
K Goodwin et al.
VACCINE (2006)
Clinical experience with inactivated, virosomal influenza vaccine
IA de Bruijn et al.
VACCINE (2005)
The bone marrow: a nest for migratory memory T cells
F Di Rosa et al.
TRENDS IN IMMUNOLOGY (2005)
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: A potential priming strategy
I Stephenson et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Influenza and its relationship to circulatory disorders
DM Fleming et al.
EPIDEMIOLOGY AND INFECTION (2005)
Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity
L Bungener et al.
VACCINE (2005)
Virosomes for antigen and DNA delivery
T Daemen et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children
G Kanra et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly
BR Ruf et al.
INFECTION (2004)
Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
D Felnerova et al.
CURRENT OPINION IN BIOTECHNOLOGY (2004)
Serum antibody responses after intradermal vaccination against influenza
RB Belshe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers
IA de Bruijn et al.
VIRUS RESEARCH (2004)
Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults:: phase I randomised trial
I Stephenson et al.
LANCET (2003)
Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity
DJ Marciani
DRUG DISCOVERY TODAY (2003)
A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis
A Banzhoff et al.
GERONTOLOGY (2003)
Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly
KL Nichol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
I Stephenson et al.
VACCINE (2003)
Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects
S Squarcione et al.
VACCINE (2003)
Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity
A Huckriede et al.
VACCINE (2003)
Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems
R Glück et al.
VACCINE (2003)
Mortality associated with influenza and respiratory syncytial virus in the United States
WW Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Cutting edge: Impaired toll-like receptor expression and function in aging
M Renshaw et al.
JOURNAL OF IMMUNOLOGY (2002)
Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations
E Hak et al.
CLINICAL INFECTIOUS DISEASES (2002)
Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study
MC Zambon et al.
LANCET (2001)
Comparison of three different influenza vaccines in institutionalised elderly
V Baldo et al.
VACCINE (2001)
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
A Podda
VACCINE (2001)
分享论文
